

Pharmaceutical Benefits Advisory Committee

Email: PBAC@health.gov.au

Address all mail to:
PBAC Secretariat
GPO Box 9848
Canberra ACT 2601

DELISTING OF PHARMACEUTICAL BENEFIT ITEMS EFFECTIVE 01 DECEMBER 2024

Following is the advice of the Pharmaceutical Benefits Advisory Committee (PBAC) concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act 1953*, with effect from the above date.

Item

PBAC Advice

Carmellose with glycerin

The sponsor requested the delisting of Optive® (carmellose with glycerin) from the Pharmaceutical Benefits Scheme (PBS).

The PBAC noted there are alternative lubricating eye drops available. The PBAC advised the delisting of this product would not result in an unmet clinical need.

Cefepime

The sponsor requested the delisting of Cefepime Kabi (cefepime 1 gram and 2 gram injections) from the PBS.

The PBAC noted that cefepime is an important medicine for the treatment of febrile neutropenia and most of its use is in public hospitals and therefore not on the PBS. The PBAC considered that while delisting cefepime from the PBS would likely not significantly affect patient access, discontinuation of the product would cause problems in clinical practice. The PBAC advised the delisting of this product may result in an unmet clinical need and requested that the Department seek to retain these products on the PBS.

Brendon Wheatley
Director (A/g), PBAC Governance
Office of Health Technology Assessment
Technology Assessment and Access Division
20 November 2024